DBV Technologies (DBVT) Restructuring Costs (2020 - 2021)
DBV Technologies (DBVT) reported Restructuring Costs of $438000.0 for Q4 2021, down 82.82% year-over-year from $2.5 million in Q4 2020, and down 82.82% quarter-over-quarter from $2.5 million in Q4 2020.
DBV Technologies (DBVT) Restructuring Costs (2020 - 2021) Analysis & Trends
DBV Technologies (DBVT) has 2 years of Restructuring Costs data on file, last reported at $438000.0 in Q4 2021.
- Restructuring Costs for Q4 2021 came in at $438000.0, down 82.82% year-over-year; the trailing twelve-month figure through Dec 2021 was $438000.0 (changed N/A YoY), and the FY2021 annual result was $438000.0, down 95.33% from the prior year.
- Restructuring Costs fell to $438000.0 in Q4 2021 per DBVT's latest filing, from $2.5 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $21.3 million in Q2 2020 and troughed at -$286000.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 438,000.00 |
| Dec 31, 2020 | 2.55 Mn |
| Sep 30, 2020 | -286,000.00 |
| Jun 30, 2020 | 21.29 Mn |